World's Best Scientists 2026 revealed!
Jan H.M. Schellens

Jan H.M. Schellens

Award Badge
Medicine
Netherlands
2023

D-Index & Metrics

Medicine

D-Index
131
Citations
71769
World Ranking
2376
National Ranking
90

Research.com Recognitions

  • 2023 - Research.com Medicine in Netherlands Leader Award

Overview

Jan H.M. Schellens is affiliated with Utrecht University in the Netherlands and has an extensive research profile focused primarily on medicine and biochemistry, genetics, and molecular biology. Their work spans multiple subfields, with significant contributions to oncology, molecular biology, pulmonary and respiratory medicine, cancer research, and radiology, nuclear medicine, and imaging.

Their main research topics include colorectal cancer treatments and studies, lung cancer treatments and mutations, signaling pathways such as PI3K/AKT/mTOR in cancer, cancer genomics and diagnostics, melanoma and MAPK pathways, PARP inhibition in cancer therapy, and cancer treatment and pharmacology.

Jan H.M. Schellens has contributed to a number of recent papers, highlighting involvement in clinical cancer research and therapeutic trials. Notable publications include:

  • Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial, 2020, The Lancet Oncology
  • Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study, 2022, Annals of Oncology
  • Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial, 2023, Nature Medicine
  • Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study, 2020, Cancer
  • A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours, 2020, British Journal of Cancer

Frequent co-authors who have collaborated with Jan H.M. Schellens include:

  • Jos H. Beijnen
  • Hilde Rosing
  • Alwin D. R. Huitema
  • Jonathan E. Knikman
  • Annemieke Cats

Publications featuring Jan H.M. Schellens frequently appear in several distinguished scientific journals such as Annals of Oncology, British Journal of Cancer, Clinical Pharmacology & Therapeutics, Clinical Cancer Research, and Cancer Research.

Best Publications

  • Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

    Peter C Fong;David S Boss;Timothy A Yap;Andrew Tutt

  • Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.

    M Maliepaard;G L Scheffer;I F Faneyte;M A van Gastelen

  • Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

    Scott Kopetz;Axel Grothey;Rona Yaeger;Eric Van Cutsem

  • A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent

    Jeany M. Rademaker-Lakhai;Desiree van den Bongard;Dick Pluim;Jos H. Beijnen

  • Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval

    Peter C. Fong;Timothy A. Yap;David S. Boss;Craig P. Carden

  • Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.

    John D Allen;Arnold van Loevezijn;Jeany M Lakhai;Martin van der Valk

  • Photodynamic Therapy in Oncology

    Martijn Triesscheijn;Paul Baas;Jan H. M. Schellens;Jan H. M. Schellens;Fiona A. Stewart

  • Role of Breast Cancer Resistance Protein in the Bioavailability and Fetal Penetration of Topotecan

    Johan W. Jonker;Johan W. Smit;Remco F. Brinkhuis;Marc Maliepaard

  • Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer

    Vivek Subbiah;Robert J. Kreitman;Zev A. Wainberg;Jae Yong Cho

  • An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons.

    Esther F.A Brandon;Christiaan D Raap;Irma Meijerman;Jos H Beijnen;Jos H Beijnen

  • Clinical pharmacokinetics of therapeutic monoclonal antibodies.

    Ron J. Keizer;Alwin D. R. Huitema;Jan H. M. Schellens;Jan H. M. Schellens;Jos H. Beijnen;Jos H. Beijnen

  • Overexpression of the BCRP/MXR/ABCP Gene in a Topotecan-selected Ovarian Tumor Cell Line

    Maliepaard M;van Gastelen Ma;de Jong La;Pluim D

  • Approaching tumour therapy beyond platinum drugs : status of the art and perspectives of ruthenium drug candidates.

    A. Bergamo;C. Gaiddon;J.H.M. Schellens;J.H. Beijnen

  • Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

    Ursula Amstutz;Linda M. Henricks;Steven M. Offer;Julia Barbarino

  • The Effect of Bcrp1 (Abcg2) on the In vivo Pharmacokinetics and Brain Penetration of Imatinib Mesylate (Gleevec): Implications for the Use of Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors to Enable the Brain Penetration of Imatinib in Patients

    Pauline Breedveld;Dick Pluim;Greta Cipriani;Peter Wielinga

  • Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer

    Ryan B. Corcoran;Thierry Andre;Chloe E. Atreya;Jan H.M. Schellens

  • Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy

    Suzanne Leijen;Sjaak A. Burgers;Paul Baas;Dick Pluim

  • Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs.

    Pauline Breedveld;Jos H. Beijnen;Jos H. Beijnen;Jan H.M. Schellens;Jan H.M. Schellens

  • Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors

    K.M. Heinhuis;W. Ros;M. Kok;N. Steeghs

  • Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.

    Vivek Subbiah;Ulrik Lassen;Elena Élez;Antoine Italiano

Frequent Co-Authors

Jos H. Beijnen
Jos H. Beijnen Utrecht University
Hilde Rosing
Hilde Rosing Antoni van Leeuwenhoek Hospital
Emile E. Voest
Emile E. Voest Antoni van Leeuwenhoek Hospital
Alfred H. Schinkel
Alfred H. Schinkel Antoni van Leeuwenhoek Hospital
Josep Tabernero
Josep Tabernero Vall d´Hebron Institute of Oncology
Stan B. Kaye
Stan B. Kaye Royal Marsden NHS Foundation Trust
Jaap Verweij
Jaap Verweij Erasmus University Rotterdam
Ron H.J. Mathijssen
Ron H.J. Mathijssen Erasmus University Rotterdam
Ahmad Awada
Ahmad Awada Université Libre de Bruxelles
Henk-Jan Guchelaar
Henk-Jan Guchelaar Leiden University Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative routes within the medical field can open doors to rewarding careers and specialized expertise. For those interested in healthcare administration or working behind the scenes, obtaining the cheapest medical coding certification online is a smart way to gain in-demand skills without a significant financial burden.

If direct patient care is your passion, you might consider one of the most affordable online nurse practitioner programs. These programs allow nurses to expand their roles and provide higher levels of care. Affordable options are also available for those seeking advanced nursing degrees, with the cheapest online msn programs offering flexible pathways to leadership or specialized positions.

For those aiming for top-tier roles in research, education, or advanced clinical practice, pursuing an online nursing doctorate can be a significant step forward. Each of these pathways offers scalable opportunities for growth and advancement within the dynamic healthcare sector.

Best Scientists Citing Jan H.M. Schellens

Trending Scientists

Recently Published Articles